Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517920 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 study of Advanced Hepatocellular Carcinoma, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 6
- Study locations
NCT00517920: Completed Phase 2 study of Advanced Hepatocellular Carcinoma, sponsored by AbbVie (prior sponsor, Abbott).
NCT00517920 is a Phase 2 study of Advanced Hepatocellular Carcinoma that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 44 participants, below the 85-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (48% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00517920, a Phase 2 study of Advanced Hepatocellular Carcinoma, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
Conditions Studied
Interventions
- DRUG ABT-869
Study Locations (6)
Other
- Site Reference ID/Investigator# 7169 - Toronto
- Site Reference ID/Investigator# 5837 - Vancouver
- Site Reference ID/Investigator# 5235 - Singapore
- Site Reference ID/Investigator# 5611 - Singapore
- Site Reference ID/Investigator# 6265 - Taipei
Pennsylvania
- Site Reference ID/Investigator# 7726 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT00517920 record still lists
NCT00517920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 85-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ABT-869 is the first listed.
NCT00517920 lists 6 locations in 2 states (Other, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00517920 about?
NCT00517920 is a clinical study titled "Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)". Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
What is the current status of trial NCT00517920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2007-09. Estimated completion is 2012-06.
What conditions does trial NCT00517920 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma.
What interventions are being tested in trial NCT00517920?
The interventions under investigation include: ABT-869 (DRUG).
Who is sponsoring clinical trial NCT00517920?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00517920 being conducted?
This trial has 6 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00517920's enrollment target sits among peer trials
44 9th of 16 higher than 8 of 16 other Advanced Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
RECRUITING · Phase 2
-
Ligufalimab and Cadonilimab in Advanced Liver Cancers
RECRUITING · Phase 2
-
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
COMPLETED · Phase 2
-
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
COMPLETED · Phase 2
-
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia